Biolase released its preliminary financial results Oct. 21 for the third quarter ended Sept. 30.
For the third quarter, Biolase expects revenue to range between $8.5 million and $8.8 million. However, the company is anticipating loss for operations to be between $4.8 million and $5.2 million. Biolase has increased its allowance for doubtful accounts by around $1.1 million to reserve for payments still owed to Chinese distributors.
Biolase predicts its net loss for the quarter to be in the range of $5.4 million to $5.8 million. Third quarter earnings before interest, tax, depreciation and amortization are expected to represent a loss between $2.7 million and $3.1 million.
For the fourth quarter, Biolase expects to break even. Historically, the fourth quarter has been the company's strongest performing quarter.
More articles on dental:
Fire destroys Chicago dental care mobile
TDSC reassures dentists after judge finds Benco, Patterson conspired against buying groups
Washington state dental operator fined $5K in connection with patient death
For the third quarter, Biolase expects revenue to range between $8.5 million and $8.8 million. However, the company is anticipating loss for operations to be between $4.8 million and $5.2 million. Biolase has increased its allowance for doubtful accounts by around $1.1 million to reserve for payments still owed to Chinese distributors.
Biolase predicts its net loss for the quarter to be in the range of $5.4 million to $5.8 million. Third quarter earnings before interest, tax, depreciation and amortization are expected to represent a loss between $2.7 million and $3.1 million.
For the fourth quarter, Biolase expects to break even. Historically, the fourth quarter has been the company's strongest performing quarter.
More articles on dental:
Fire destroys Chicago dental care mobile
TDSC reassures dentists after judge finds Benco, Patterson conspired against buying groups
Washington state dental operator fined $5K in connection with patient death